This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Relapsing polychondritis (relapsing polychondritis)Relapsing Polychondritis

A.Classification codesICD-10 M94.1 | Special Copayment Reduction V178
B.Synonyms—
C.Adult onsetHigh — typically first diagnosed in adults in their 30s to 60s; pediatric onset is rare.
1.HistoryDescribed by Jaksch-Wartenhorst (1923); diagnostic criteria established by McAdam in 1960.
2.CausesAutoimmune mechanism; autoantibodies against type II collagen and matrilin-1.
3.GeneticsHLA-DR4 association; some HLA-B27; no single-gene cause.
4.General epidemiologyVery rare; annual incidence 3.5/1,000,000; 30s to 60s, males and females equally.
5.PathophysiologyAutoimmune response against cartilage matrix proteins; inflammation·destruction → fibrosis·collapse.
6.SymptomsRecurrent auricular chondritis (auricular redness·swelling), nasal chondritis, airway chondritis, arthritis.
7.SignsAuricular redness·deformity, nasal septal collapse (saddle nose), airway stenosis, scleritis.
8.ScreeningNo specific screening test; apply McAdam criteria when clinically suspected.
9.DiagnosisMcAdam/Damiani-Levine criteria; airway CT; tissue biopsy; autoantibodies.
10.TreatmentMild: NSAIDs·dexamethasone; moderate–severe: prednisone + immunosuppressants; biologics.
11.PrognosisEpisodic course; increased mortality with airway·cardiovascular involvement.
12.PreventionNo established prevention; prevention of organ involvement through early diagnosis·treatment.
13.ReferencesList of key references and guidelines

1. History

Relapsing polychondritis (RP) was first reported in 1923 when the Austrian physician Rudolf Jaksch-Wartenhorst described a patient with recurrent inflammation of the auricular and nasal cartilage, arthritis, and fever as 'polychondropathia'. Later, in 1960, McAdam and colleagues in the United States proposed six diagnostic criteria, laying the foundation for the modern diagnostic system, and in 1976 Damiani and Levine modified and supplemented these to establish the diagnostic criteria widely used today. The name 'relapsing' reflects the episodic, recurrent nature of this disease.

Initially there were only isolated reports of rare cases, but with advances in immunofluorescence and autoantibody techniques, the autoimmune mechanism against type II collagen and matrilin-1 was elucidated and a systematic understanding began. In the 1990s–2000s, an association with HLA-DR4 was reported, and treatment strategies expanded as biologics (TNF inhibitors, interleukin inhibitors, etc.) were added to the treatment options. It is classified as M94.1 in ICD-10 and is a rare autoimmune disease assigned the Korean Special Copayment Reduction code V178.

2. Causes

An autoimmune mechanism is central to the cause of relapsing polychondritis. Autoantibodies and T-cell-mediated immune responses against type II collagen, matrilin-1, and cartilage oligomeric matrix protein (COMP), the major constituent proteins of the cartilage matrix, have been identified as the direct cause of cartilage destruction. Anti-matrilin-1 antibodies in particular occur relatively specifically in RP and are associated with auricular chondritis and airway involvement.

What triggers this autoimmune response is not yet clear. There are hypotheses that infection (viral, bacterial), trauma, chemical exposure, etc. can initiate autoimmunity through molecular mimicry or epitope exposure, but there is no definitive evidence. RP is observed to be accompanied by other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, vasculitis, myelodysplastic syndrome, etc.) in about 30–50% of cases, suggesting a shared immune susceptibility.

3. Genetics

No single-gene cause of relapsing polychondritis has been identified. However, HLA (human leukocyte antigen) association studies have repeatedly reported that HLA-DR4 is overrepresented in RP patients. HLA-DR4 plays an important role in the autoimmune response to type II collagen and is a genetic risk factor also shared with rheumatoid arthritis. Some studies report that HLA-B27 positivity is associated with spondyloarthritis-like features of RP.

Familial clustering is very rare, and RP occurs mainly sporadically. This suggests that the combined action of polygenic susceptibility and environmental triggers, rather than a single-gene mutation, is involved in disease onset. Genome-wide association studies (GWAS) have not yet been sufficiently performed, so information on additional susceptibility genes is limited.

4. General epidemiology

Relapsing polychondritis is a very rare disease, with an estimated annual incidence of about 3.5 per million population. Age of onset ranges from 20 to 80 years but is most common in the 30s to 60s, with a median age of onset of about 45–50 years. Regarding sex differences, early studies reported a female predominance, but recent large-scale studies have in some cases shown equal distribution or a slight male predominance, so findings are inconsistent. It occurs in all races and is not limited to any particular race.

In Korea, epidemiology can be estimated from the number of patients registered for Special Copayment Reduction (V178), but national statistical data are limited. Accompanying autoimmune diseases are present in 30–50% of all cases, and coexistence with systemic lupus erythematosus, vasculitis, and myelodysplastic syndrome in particular is clinically important. Some literature reports that the HLA-DR4 association seen in Caucasians is similarly observed in Korean and East Asian patients.

5. Pathophysiology

The pathophysiology of relapsing polychondritis can be summarized as the initiation and perpetuation of an autoimmune response against cartilage matrix proteins. Molecularly, type II collagen and matrilin-1 of the cartilage matrix are the main targets of autoimmune attack. When a triggering event (infection, trauma, etc.) exposes cartilage epitopes to the immune system, autoreactive T cells and B cells are activated, and autoantibody production and cell-mediated immunity begin. This immune response induces infiltration of cartilage tissue by neutrophils, macrophages, and T cells, and a storm of cytokines (IL-1β, TNF-α, IL-6, IL-17).

Matrix metalloproteinases (MMPs) and reactive oxygen species secreted by inflammatory cells degrade the cartilage matrix, and repeated episodes lead to progressive destruction of cartilage tissue. Destruction of the auricular cartilage produces the characteristic 'cauliflower ear' deformity, and destruction of the nasal cartilage results in a saddle nose deformity. Involvement of the tracheal and bronchial cartilage causes the most dangerous complication, airway stenosis, and involvement of cardiovascular cartilage (aortic valve, aortic wall) can lead to aortic aneurysm and valvular regurgitation.

6. Symptoms

The clinical presentation of relapsing polychondritis is highly variable, and any cartilaginous tissue can be involved. The most characteristic first symptom is auricular chondritis, in which the auricle (pinna) rapidly becomes red, swollen, and tender. Characteristically, the earlobe (the part without cartilage) is not involved. When this symptom recurs repeatedly, the ear cartilage is destroyed and a drooping deformity of the auricle develops. Nasal chondritis causes redness and tenderness of the nose, and when it recurs, a saddle nose deformity develops.

Airway involvement (tracheobronchial chondritis) is the most life-threatening complication, presenting with hoarseness, cough, dyspnea, and inspiratory stridor, with a risk of acute airway obstruction. Nonerosive polyarthritis, episcleritis and scleritis, vestibular involvement (hearing loss, dizziness), and cardiovascular involvement (aortic regurgitation, ECG abnormalities) also occur. Systemic symptoms such as fever, fatigue, and weight loss accompany episodes. An episodic course of symptom flares and remissions is typical, but in some it is a continuously progressive form.

7. Signs

In the acute phase of auricular chondritis, diffuse redness, swelling, and tenderness of the auricle are observed, and 'earlobe sparing in auricular redness', in which the earlobe is not involved, is a diagnostically important finding. After repeated episodes, the auricular cartilage is destroyed and a soft, deformed auricle is observed. Destruction of the nasal septal cartilage produces a 'saddle deformity' of the nose, with the typical appearance of depression of the middle third of the external nose. With laryngeal and tracheal involvement, tenderness on palpation of the larynx, inspiratory wheezing, decreased breath sounds, etc. appear.

Ophthalmic findings may include episcleritis (erythema, tenderness), scleritis (deep injection, severe pain), and uveitis. Joint involvement presents with polyarticular swelling, tenderness, and limited range of motion, but bone erosions are rare. Heart murmurs (aortic valve regurgitation), arrhythmias, and skin lesions (erythema nodosum-like, purpura) may also be identified as signs. Laboratory findings include elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), mild anemia, and positive anti-matrilin-1 antibodies.

8. Screening

There is no single screening test specific to relapsing polychondritis. The disease is fundamentally a clinical syndrome, and recognizing its characteristic clinical presentation is key. Suspecting RP in patients with a combination of recurrent auricular redness (earlobe sparing), nasal chondritis, and airway symptoms is the starting point for early detection. When clinically suspected, ESR, CRP, complete blood count, and anti-matrilin-1 antibody testing are performed first.

Next, chest CT (assessment of tracheal and bronchial wall thickening and stenosis), pulmonary function tests (extrathoracic airway obstruction pattern on the flow-volume curve), otolaryngologic endoscopy, and ophthalmologic examination are needed. If myelodysplastic syndrome or another autoimmune disease is suspected, related tests are added. Rather than the concept of screening, 'suspicion → immediate specialist referral and comprehensive evaluation' is the basic strategy in managing this disease.

9. Diagnosis

The McAdam (1976) criteria are basically used for the diagnosis of relapsing polychondritis. A clinical diagnosis is possible when 3 or more of 6 criteria (bilateral auricular chondritis, nonerosive seronegative polyarthritis, nasal chondritis, ocular inflammation, airway chondritis, inner ear dysfunction) are met. Damiani and Levine modified these so that diagnosis is also possible based on histological findings, including 1 or more criteria with histological confirmation, or 2 or more criteria with response to treatment (steroids).

Auricular cartilage biopsy characteristically shows perichondrial inflammation, neutrophil and lymphocyte infiltration, loss of cartilage matrix, and fibrosis. On airway CT, anterior and lateral thickening of the tracheal and bronchial walls (with sparing of the posterior membranous portion) is a characteristic finding of RP. Anti-matrilin-1 and anti-type II collagen antibodies are not highly specific, but a positive result supports the diagnosis. Differential diagnoses include granulomatosis with polyangiitis (GPA), recurrent auricular perichondritis, traumatic ear deformity, cocaine-induced nasal septal perforation, and sarcoidosis.

10. Treatment

Treatment of relapsing polychondritis is determined stepwise according to the severity of episodes and the organs involved. Mild (auricular·nasal cartilage episodes): symptoms can be controlled with NSAIDs (indomethacin, etc.) or low-dose oral dexamethasone·prednisone (0.5 mg/kg/day). Moderate to severe (airway, ocular, cardiovascular involvement): high-dose prednisone (1 mg/kg/day) is the standard treatment, and when the response is insufficient or the steroid dose is difficult to taper, immunosuppressants (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide) are combined.

In refractory or severe airway·systemic involvement, use of biologics such as TNF-α inhibitors (infliximab, adalimumab), IL-6 receptor inhibitors (tocilizumab), and CTLA4-Ig (abatacept) has been reported in case reports and small studies. When there is a risk of acute airway obstruction due to airway stenosis, emergency airway management such as endotracheal intubation·tracheostomy and endobronchial stent placement is needed. Severe aortic regurgitation or aortic aneurysm may require cardiac surgery.

11. Prognosis

The prognosis of relapsing polychondritis is quite heterogeneous, ranging from a chronic course of relapses and remissions over several decades to rapid progression leading to death within several years. The most important prognostic determinants are the presence of airway involvement and cardiovascular involvement. Airway stenosis and collapse due to destruction of tracheal and bronchial cartilage can cause sudden airway obstruction, and aortic valve regurgitation and aortic aneurysm can lead to fatal cardiovascular complications.

Early studies in the 1980s reported a 5-year survival rate of about 74%, but the prognosis has since improved with advances in treatment and early diagnosis. The prognosis is worse when accompanied by systemic autoimmune disease (particularly lupus, vasculitis) or myelodysplastic syndrome. Ocular involvement (particularly scleritis) carries a risk of blindness, and inner ear involvement can cause permanent hearing loss. Long-term follow-up and a multidisciplinary approach are essential for early detection of complications and improvement of prognosis.

12. Prevention

There is currently no established method of primary prevention for relapsing polychondritis. Because an autoimmune response is central to the pathogenesis, avoiding autoimmune triggers (infection, certain drugs, environmental exposures) could theoretically contribute to preventing episodes, but there are no evidence-based recommendations. There is a hypothesis that early detection and treatment of accompanying autoimmune diseases or myelodysplastic syndrome may improve the immune status before the onset of RP, but this too has not been confirmed.

Prevention of episode recurrence (secondary prevention) is more important in practice. The goal is to reduce the frequency and severity of episodes through appropriate maintenance immunosuppressive therapy. Regular pulmonary function tests·airway CT for early detection of airway involvement and regular echocardiographic follow-up for cardiovascular involvement contribute to preventing long-term complications. Educating patients to visit the emergency department immediately when acute airway symptoms (dyspnea·wheezing·hoarseness) occur is an important part of preventing life-threatening complications.

13. References

  1. McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55(3):193-215. PMID: 1272069
  2. Damiani JM, Levine HL. Relapsing polychondritis — report of ten cases. Laryngoscope. 1979;89(6):929-946. PMID: 449538
  3. Mathian A, Miyara M, Cohen-Aubart F, et al. Relapsing polychondritis: a 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Pract Res Clin Rheumatol. 2016;30(2):316-333. doi:10.1016/j.berh.2016.08.001
  4. Lahmer T, Treiber M, von Werder A, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmun Rev. 2010;9(8):540-546. doi:10.1016/j.autrev.2010.02.016
  5. Arnaud L, Devilliers H, Peng SL, et al. The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev. 2012;12(2):204-209. doi:10.1016/j.autrev.2012.06.005
  6. Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol. 2004;16(1):56-61. PMID: 14673390
  7. Dib C, Moustafa SE, Mookadam M, Zehr KJ, Tajik AJ, Mookadam F. Surgical treatment of the cardiac manifestations of relapsing polychondritis: overview of 33 patients identified through literature review and the Mayo Clinic records. Mayo Clin Proc. 2006;81(6):772-776. PMID: 16734488
  8. Moulis G, Pugnet G, Costedoat-Chalumeau N, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheum Dis. 2018;77(8):1172-1178. doi:10.1136/annrheumdis-2017-212705
  9. Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998;129(2):114-122. PMID: 9669970
  10. Kingdon J, Roscamp J, Sangle S, D'Cruz D. Relapsing polychondritis: a clinical review for rheumatologists. Rheumatology (Oxford). 2018;57(9):1525-1532. doi:10.1093/rheumatology/kex464